ImmunoGen Message Board - Msg: 30919406

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: winners18	1/5/2017 4:49:58 PM
	of 5665

antibody rnai conjugate IMMU has patent on this technolgy. Also issued today was U.S. Patent 9,492,561 to IBC Pharmaceuticals, Inc., the Company’s majority-owned subsidiary, for the new patent family “Dock-and-Lock (DNL) complexes for delivery of interference RNA.” This new patent concerns compositions for targeted delivery of small interfering RNA (siRNA) to treat a variety of disease states, including cancer, autoimmune inflammatory disease, or infectious disease, and expires on arch 24, 2026. prnewswire.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next